Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial.
Journal: Psychopharmacology
Published: September 04, 2024
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.
Journal: British journal of clinical pharmacology
Published: September 28, 2021
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: May 04, 2016
Showing 1-3 of 3
Last Updated: 09/26/2026